Menu

Growth fact(or)s

2019

Approval cerabone® & maxresorb® in Argentina

Approval maxresorb® in Australia

Approval cerabone®, collprotect® membrane, Jason® membrane, mucoderm®, maxresorb® & maxresorb® inject in India

Approval Jason® membrane, cerabone® & mucoderm® in Philippines

MDSAP (Medical Device Single Audit Program) scope extension to Brazil and Japan as well as recertification for Australia, Canada and United States

botiss participation at 4 ITI congresses

2018

Approval cerabone® in USA

Approval Jason® membrane in USA

Scheduled market launch in USA, Australia, Brazil

MDSAP (Medical Devise Single Audit Program)-certification including ISO 13485:2016

botiss participation at 3 ITI congresses

Fourth bone & tissue days World Congress in Barcelona, Berlin and Warsaw

2017

CE mark approval permamem® and cerabone®

botiss participation at ITI World Symposium in Basel

2016

Third bone & tissue days World Congress in Berlin

Pre-launch of first products in the USA

Straumann takes over exclusive distribution of botiss products in Germany

2015

Market launch of maxgraft® cortico

botiss participation at 8 ITI congresses worldwide

2014

Pharmaceutical approval for maxgraft® and for maxgraft® bonebuilder

Second bone & tissue days World Congress in Berlin with 800 participants

Worldwide cooperation with Straumann in the field of regenerative products

2013

Exclusive cooperation with the Charité tissue bank for the dental regeneration

2012

First bone & tissue days World Congress in Berlin

2011

CE mark approval for mucoderm® and for maxresorb® inject

Acquisition of Cells+Tissubank Austria

2010

CE mark approval for collprotect® membrane

2009

CE mark approcal for Jason® membrane

2008

Establishment of botiss medical AG

2007

CE mark approval for maxresorb®

2002

CE mark approval for cerabone®, employed since 2006 in the dental field